Andera Partners' portfolio company Amolyt Pharma completes acquisition by
AstraZeneca

EQS-News: Andera Partners / Key word(s): Mergers & Acquisitions/Private
Equity
Andera Partners' portfolio company Amolyt Pharma completes acquisition by
AstraZeneca

15.07.2024 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Andera Partners' portfolio company Amolyt Pharma completes acquisition by
AstraZeneca

  * AstraZeneca has acquired all of Amolyt Pharma's outstanding shares for
    up to $1.05 billion.

Paris (France), Lyon (France), and Cambridge, MA (USA), July 12th, 2024 -
Andera Partners, a leading European private equity player, announced today
that its portfolio company Amolyt Pharma, a global, clinical-stage
biopharmaceutical company specializing in developing therapeutic peptides
for rare endocrine and related diseases, closed its previously announced
acquisition by the global pharmaceutical company AstraZeneca.

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage
pipeline and expands on its bone metabolism franchise with the notable
addition of eneboparatide (AZP-3601), a Phase III investigational
therapeutic peptide with a novel mechanism of action designed to meet key
therapeutic goals for hypoparathyroidism. In patients with
hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production
results in significant dysregulation of calcium and phosphate, which can
lead to life-altering symptoms and complications, including chronic kidney
disease. This programme, together with Amolyt's talented team, expertise,
and earlier pipeline, will enable Alexion's expansion into rare
endocrinology.

Under the terms of the definitive agreement, AstraZeneca has acquired all of
Amolyt Pharma's outstanding shares for a total consideration of up to $1.05
billion, on a cash and debt free basis. This includes $800 million upfront
at deal closing, plus the right for Amolyt Pharma's shareholders to receive
an additional contingent payment of $250 million payable upon achievement of
a specified regulatory milestone.

About Amolyt Pharma

Amolyt Pharma, a clinical stage biotechnology company, is building on its
team's established expertise to deliver life-changing treatments to patients
suffering from rare endocrine and related diseases. Its development
portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor
agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a
peptide growth hormone receptor antagonist for the potential treatment of
acromegaly. To learn more, visit amolytpharma.com or follow us on Twitter
and LinkedIn.

About Andera Partners

Created over 20 years ago, Andera Partners is a major player in private
company investments in France and internationally. Its teams manage EUR4.2
billion in investments in life sciences (Andera Life Sciences), growth and
buyout capital (Andera MidCap, Andera Expansion/Croissance, Andera
Co-Invest), sponsorless transactions (Andera Acto) and ecological transition
(Andera Infra).

Based in Paris, with offices in Antwerp, Milan and Munich, Andera Partners
is wholly owned by its teams, which count nearly 115 professionals, of which
69 investment professionals. It is structured as a partnership and managed
by a board of 13 partners.

Andera's 15-person life sciences team brings together extensive experience
in the life sciences industry, private equity and venture capital. Active
since 2000, the team has raised over EUR1.1 billion through its BioDiscovery
family of funds and is currently investing from its BioDiscovery 6 fund.
Since inception, the BioDiscovery funds have invested in more than 75
European and U.S. biotech and medtech companies.

For further information please visit: www.anderapartners.com

Media Contacts

  * Nicolas DELSERT, Andera Partners: +33 6 22 67 71 17,
    n.delsert@anderapartners.com

* Dr. Cora KAISER, MC Services: +49 89 210 228 0, andera@mc-services.eu


---------------------------------------------------------------------------

15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

1945551 15.07.2024 CET/CEST